News
Public · Published
Unum Group reports results for the quarter ended September 30 - Earnings Summary
Unum Group reported adjusted earnings of $2.20 per share for the quarter ended September 30, up from $2.09 a year earlier and above analysts' $2.16 average expectation. Revenue fell 24.6% to $2.55 billion, below expectations of $2.97 billion, while the company reported a $419.7 million quarterly loss.
Published:
Updated:
What happened
Unum Group reported adjusted earnings of $2.20 per share for the quarter ended September 30, up from $2.09 a year earlier and above analysts’ $2.16 average expectation. Revenue fell 24.6% to $2.55 billion, below expectations of $2.97 billion, while the company reported a $419.7 million quarterly loss.
Confirmed
Global impact / market context
The results show stronger adjusted earnings per share alongside sharply lower revenue and a reported quarterly loss. If weaker revenue persists, it could limit cash available to cover claims and operating costs; the gap between adjusted earnings and the reported loss also makes the underlying result important to assess.
Analyst inference
Analysts’ average earnings estimate had declined about 0.6% over three months, and two analysts cut estimates in the last 30 days. Yet the average rating was buy, while the life and health insurance peer group averaged hold, indicating more favorable recommendations for Unum than for peers.
Confirmed
What to watch
- Future results can show whether revenue stabilizes or continues falling; sustained weakness could constrain resources for claims and costs even if adjusted earnings per share remain positive. Analyst inference
- Compare adjusted earnings with reported results in upcoming reports to see whether the gap narrows; the current quarter included a $419.7 million loss despite $2.20 adjusted earnings per share. Analyst inference
- Analysts’ estimate revisions and recommendations may change as new results arrive; the supplied summary records two negative earnings revisions in the last 30 days and an average buy rating. Confirmed
Evidence
- Original source link unavailable